A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trialResearch article Published on 2021-12-012022-10-05 Journal: The Lancet Regional Health - Americas [Category] 유전자 메커니즘, 임상, [키워드] adverse event Anti-RBD antibody Antibody titre Asymptomatic baseline booster cellular response clinical clinical trial convalescent COVID-19 Cuba dimeric elicited ELISA ENhance Environment evaluated finding funding greater Humoral response IFN-γ IgG increase in individual inhibitory Intramuscular injection Local median Mild minor natural immunity neutralization Open-label Partial Participants PCR-positive Primary outcome producing Public reactogenicity Receptor binding domain registry Reinfection reported safety profile SARS-CoV-2 Science secondary outcome Serious Adverse Event single dose subclinical infection T cell technology TNF-α vaccination Vaccine vaccine immunogenicity Virus neutralization titre [DOI] 10.1016/j.lana.2021.100079 [Article Type] Research article
Acute myocarditis after COVID-19 vaccination with mRNA-1273 in a patient with former SARS-CoV-2 infection이전 SARS-CoV-2 감염 환자에서 mRNA-1273으로 COVID-19 백신 접종 후 급성 심근염Case Reports Published on 2021-12-012022-09-11 Journal: ESC heart failure [Category] SARS, 치료기술, 치료법, [키워드] Acute myocarditis acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Asymptomatic cardiac cardiac troponin T chest pain classical contractile coronavirus COVID-19 COVID-19 vaccination Diagnosis dysfunction echocardiography Endomyocardial biopsy first dose healthy IgG Infection infiltration Inflammation magnetic resonance imaging Moderna monocyte Monocytes mRNA mRNA-1273 myocarditis nucleocapsid protein Patient reactogenicity receiving SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus Side effect Symptom symptom onset T lymphocytes tested the patient troponin T vaccination Vaccine viral genome viral genome analysis viruses was increased [DOI] 10.1002/ehf2.13613 PMC 바로가기 [Article Type] Case Reports
Identification of Novel Malaria Transmission-Blocking Vaccine Candidates새로운 말라리아 전파 차단 백신 후보 식별Cellular and Infection Microbiology Published on 2021-11-302022-10-31 Journal: Frontiers in Cellular and Infection Microbiology [Category] Coronavirus, MERS, SARS, 말라리아, [키워드] accelerate addition approach candidate children clinical development Control COVID-19 develop Efficacy effort Human humans identification immuno-profiling include malaria measure morbidity and mortality novel Plasmodium Plasmodium falciparum reached reactogenicity reduce reduced required Research reverse vaccinology Significant significantly sub-Saharan Africa the WHO Transmission Transmission-blocking vaccine (TBV) Vaccine Vaccines wheat germ cell-free system (WGCFS) widespread [DOI] 10.3389/fcimb.2021.805482 PMC 바로가기 [Article Type] Cellular and Infection Microbiology
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunitySARS-COV-2 T 세포 면역의 유도를위한 COVID-19 펩티드 백신Clinical Trial Published on 2021-11-232022-08-13 Journal: Nature [Category] MERS, SARS, 변종, 임상, 치료기술, 치료법, 치료제, [키워드] All study participants analysed Analysis approved B cell CD4 CD8 composed conducted CoVac-1 COVID-19 deficiency end point Epitopes event Follow-up granuloma IFNγ Immunity immunogencity immunogenicity induce Local Mild Montanide ISA51 multifunctional Open-label open-label trial participant Patient peptide Peptide vaccines peptide-based peptide-based vaccine peptides Phase I Phase I trials primary end point reactogenicity receptor safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine SARS-CoV-2 variant Serious Adverse Event Serious Adverse Events Study participants surpassed systemic reactogenicity T cell T cell epitope T cell epitopes T cell response T cell responses T cells T helper Toll-like receptor Trial vaccination Vaccine Vaccines variant Viral viral infection viral infections Viral protein Viral proteins [DOI] 10.1038/s41586-021-04232-5 PMC 바로가기 [Article Type] Clinical Trial
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley RatsSprague Dawley 쥐에서 SARS-CoV-2의 스파이크 단백질을 발현하는 뉴캐슬병 바이러스(NDV-HXP-S)의 안전성 및 면역원성 분석Immunology Published on 2021-11-182022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 진단, 치료기술, [키워드] (Alpha) (Beta acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered administration Alpha animal model Antibody titer Antibody titers approach B.1.1.7 B.1.351 B.1.617.2 Beta boost Brazil clinical clinical testing coronavirus country COVID-19 elicited expand expressing followed by Histopathology Immunity immunogenicity immunogenicity analysis induce intramuscularly intranasally Local mucosal Neutralizing activity newcastle disease virus performed Post-mortem pre-fusion RAT rat model reactogenicity regimen Region respiratory robust Safety SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 vaccine second serum antibodies serum antibody severe acute respiratory syndrome Coronavirus Spike protein Spread systemic reactions tested the Spike the spike protein the United State the vaccine Toxicity United States vaccination vaccination rate Vaccine vaccine administration variants of concern VOCs were assessed wild type [DOI] 10.3389/fimmu.2021.791764 PMC 바로가기 [Article Type] Immunology
Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central EuropeArticle Published on 2021-11-162022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] 95% CI Active surveillance Administered Adverse adverse effects adverse event adverse events Adverse reactions Affect age Analysis AstraZeneca BTN162 mRNA vaccine Care carried concerning COVID-19 COVID-19 vaccination COVID-19 vaccines cross-sectional cross-sectional study demographic data Descriptive statistics doses Europe European country fatigue females groups headache healthcare healthcare personnel Healthcare workers increased risk injection Local Logistic regression Mild Moderna mRNA-based mRNA-based vaccine mRNA-based vaccines Occurrence optimization Pain parameters participant performed Pfizer-BioNTech Poland pooled analysis Prevalence proportion PROTECT question questionnaire reactogenicity recipient reported Result second dose secure selected significantly students systemic reaction systemic side effect vaccination Vaccine Vaccines vector vaccine viral vector-based vulnerable patients with COVID-19 worker [DOI] 10.3390/jcm10225338 PMC 바로가기 [Article Type] Article
Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon상동 BNT162b2 백신과 비교하여 BBIBP-CorV 백신을 접종한 개인에서 BNT162b2 부스터의 면역원성 및 반응성: 레바논의 파일럿 전향 코호트 연구 결과Article Published on 2021-11-052022-09-11 Journal: Vaccine [Category] SARS, 변종, [키워드] 95%CI Administered anti-Spike IgG BBIBP-CorV BNT162b2 booster booster dose booster vaccination ChAdOx1 ChAdOx1-S Combination conducted country COVID-19 dose Effectiveness elicited General Hospital geometric mean geometric mean titer heterologous immunization homologous Homologous immunization immunization immunogenicity individual Lebanon. mRNA vaccine mRNA vaccines of BNT162b2 overcome Population prospective cohort study reactogenicity Result Safe significantly tested the vaccine vaccination Vaccine variants [DOI] 10.1016/j.vaccine.2021.10.007 PMC 바로가기 [Article Type] Article
Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in ItalyArticle Published on 2021-11-032022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] activity Adverse reaction Adverse reactions age BNT162b2 mRNA vaccine conducted COVID-19 COVID-19 pandemic dose doses event fatigue female females Fever first dose headache healthcare worker Healthcare workers IMPROVE individuals intensity IRCCS Italy Local local pain mass mass vaccination campaign moderate mRNA mRNA vaccine occupational health of BNT162b2 participant Participants physician Population Prevalence reaction reactogenicity receive reference Regional reported School second dose second vaccination survey systemic Teaching university vaccination working [DOI] 10.3390/vaccines9111269 PMC 바로가기 [Article Type] Article
Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers이전에 SARS-CoV-2 감염 및 감염되지 않은 의료 종사자의 비활성화된 SARS-CoV-2 백신(CoronaVac)의 면역원성 및 반응성 비교Comparative Study Published on 2021-11-022022-09-11 Journal: Human vaccines & immunotherapeutics [Category] MERS, SARS, 진단, 치료기술, [키워드] administration Adverse reaction Adverse reactions antibody antibody levels Antibody Response Antibody titer Antibody titers Asymptomatic Care CoronaVac detection dose Effect elicit enrolled first dose HCW HCWs Health Health care Health care worker health care workers health-care Hospitalized immunized immunogenicity inactivated infected individual infected individuals infections intramuscularly median Mild nasopharyngeal natural infection not differ Pneumonia questionnaire RBD reactogenicity Receptor-binding domain reported respiratory Respiratory tract infections Safe SARS-CoV-2 SARS-coV-2 inactivated virus vaccine SARS-CoV-2 positivity SARS-CoV-2 spike protein SARS-CoV-2 vaccine second dose Seven significantly higher Spike protein the receptor-binding domain the vaccine Turkey uninfected upper respiratory tract upper respiratory tract infections vaccination Vaccine vaccine administration vaccine adverse effects vaccine antibody response. vaccine dose virus was done [DOI] 10.1080/21645515.2021.1953344 PMC 바로가기 [Article Type] Comparative Study
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort studyChAdOx1 nCoV-19 및 BNT162b2를 사용한 동종 및 이종 프라임-부스트 면역의 안전성, 반응성 및 면역원성: 전향적 코호트 연구Observational Study Published on 2021-11-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI Alpha anti-RBD Anti-RBD IgG Anti-S1 AstraZeneca B.1.1.7 B.1.351 Berlin Beta Beta variant beta variants binding BNT162b2 boost booster Cambridge ChAdOx1 ChAdOx1 nCoV-19 Concentration COVID-19 COVID-19 vaccines Cutoff dose education enrolled geometric mean Germany health-care Heterologous heterologous prime-boost highest homologous IFN-γ IgG levels immunisation immunogenicity IMPROVE inhibitory interim analysis IQR Mainz median mitigate neutralisation test participant Pfizer-BioNTech prospective cohort study prospective observational cohort pseudovirus neutralisation assay questionnaire RBD IgG RBD-ACE2 reactivity reactogenicity receiving recipient recipients regimen reported Safety SARS-CoV-2 S1 SARS-CoV-2 virus SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody second vaccination specific antibodies supply shortage Symptom systemic systemic symptoms T-cell vaccination Vaccine variants of concern was measured [DOI] 10.1016/S2213-2600(21)00357-X PMC 바로가기 [Article Type] Observational Study